WT1 LAMP mRNA DC

DRUG4 trials

Sponsors

Antwerp University Hospital

Conditions

Diffuse intrinsic pontine glioma (DIPG)Glioblastoma grade IVHigh-grade glioma (HGG)Malignant Pleural MesotheliomaMalignant pleural mesotheliomaepithelioid subtype (stage I-IV)

Phase 2

First-line immunotherapy using Wilms’ tumor protein 1 (WT1)-targeted dendritic cell vaccinations for malignant pleural mesothelioma

CompletedCTIS2024-517970-35-00

Antwerp University HospitalMalignant Pleural Mesothelioma

Start: 2017-10-03End: 2025-03-09Target: 30Updated: 2025-01-20

Adjuvant dendritic cell immunotherapy complementing conventional therapy for pediatric patients with high-grade glioma and diffuse intrinsic pontine glioma

CompletedCTIS2024-515295-12-00

Antwerp University HospitalDiffuse intrinsic pontine glioma (DIPG), High-grade glioma (HGG)

Start: 2021-10-06End: 2025-08-31Target: 10Updated: 2025-01-20

Adjuvant dendritic-cell immunotherapy plus temozolomide following surgery and chemoradiation in patients with newly diagnosed glioblastoma

Active, not recruitingCTIS2024-515291-13-00

Antwerp University HospitalGlioblastoma grade IV

Start: 2016-04-01Target: 20Updated: 2026-01-22

Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into platinum/pemetrexed-based first-line treatment for epithelioid malignant pleural mesothelioma

RecruitingCTIS2024-515293-27-00

Antwerp University Hospitalepithelioid subtype (stage I-IV), Malignant pleural mesothelioma

Start: 2023-02-24Target: 15Updated: 2026-01-22